Equities research analysts expect Novartis (NYSE:NVS) to report $1.33 earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Novartis’ earnings. Novartis reported earnings per share of $1.13 during the same quarter last year, which would indicate a positive year-over-year growth rate of 17.7%. The firm is scheduled to issue its next earnings report before the market opens on Thursday, April 19th.
According to Zacks, analysts expect that Novartis will report full-year earnings of $5.33 per share for the current fiscal year, with EPS estimates ranging from $5.31 to $5.35. For the next financial year, analysts forecast that the business will report earnings of $5.75 per share, with EPS estimates ranging from $5.55 to $6.00. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Novartis.
Novartis (NYSE:NVS) last released its quarterly earnings results on Wednesday, January 24th. The company reported $1.20 EPS for the quarter, beating analysts’ consensus estimates of $1.16 by $0.04. The business had revenue of $12.92 billion during the quarter, compared to analyst estimates of $12.65 billion. Novartis had a return on equity of 16.03% and a net margin of 15.69%. Novartis’s quarterly revenue was up 4.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.14 EPS.
NVS traded down $1.26 during midday trading on Monday, reaching $79.59. 1,270,454 shares of the company’s stock traded hands, compared to its average volume of 1,658,544. The firm has a market capitalization of $187,366.31, a price-to-earnings ratio of 16.55, a PEG ratio of 1.81 and a beta of 0.74. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.21 and a quick ratio of 0.91. Novartis has a 52 week low of $72.67 and a 52 week high of $94.19.
Several hedge funds have recently bought and sold shares of the business. Garland Capital Management Inc. grew its holdings in shares of Novartis by 1.0% during the 4th quarter. Garland Capital Management Inc. now owns 52,233 shares of the company’s stock worth $4,385,000 after acquiring an additional 535 shares during the period. Tradition Capital Management LLC grew its holdings in shares of Novartis by 0.9% during the 4th quarter. Tradition Capital Management LLC now owns 69,381 shares of the company’s stock worth $5,825,000 after acquiring an additional 652 shares during the period. Commerce Bank grew its holdings in shares of Novartis by 2.4% during the 4th quarter. Commerce Bank now owns 28,004 shares of the company’s stock worth $2,352,000 after acquiring an additional 664 shares during the period. West Oak Capital LLC grew its holdings in shares of Novartis by 4.4% during the 4th quarter. West Oak Capital LLC now owns 15,860 shares of the company’s stock worth $1,332,000 after acquiring an additional 665 shares during the period. Finally, Lenox Wealth Management Inc. grew its holdings in shares of Novartis by 6.9% during the 3rd quarter. Lenox Wealth Management Inc. now owns 10,585 shares of the company’s stock worth $908,000 after acquiring an additional 683 shares during the period. Hedge funds and other institutional investors own 10.76% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by WKRB News and is the sole property of of WKRB News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.wkrb13.com/2018/04/02/1-33-earnings-per-share-expected-for-novartis-nvs-this-quarter.html.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.